Table 3 Summary of events
From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
AE grade | Number (% of AE) | Sex, male N | Age, mean (range) | Ratio ENG: ACVRL1: SMAD4: not known | Dose, mg/kg | Dose, mg/day, mean (range) | Number of patients | Mean months of treatment at AE | |
|---|---|---|---|---|---|---|---|---|---|
BZB | 1 | 5 (15) | 2 | 65 (61–69) | 1:3:0:1 | 5 | 5 | 44.8 | |
2 | 17 (51) | 1 | 60.3 (35–72) | 0:9:1:7 | 5 | 10 | 45.6a | ||
3 | 10 (30) | 2 | 56.9 (54–73) | 0:5:0:5 | 5 | 5 | 36.8b | ||
4 | 0 | – | – | – | – | – | – | – | |
5 | 1 (3) | 1 | 67 | 1:0:0:0 | 5 | – | 1 | 36 | |
TH | 1 | 8 (21) | 5 | 67 (50–90) | 2:5:0:0 | – | 75 (25–100) | 7 | 41.5 |
2 | 20 (54) | 15 | 64.2 (53–81) | 9:6:1:0 | 98 (50–200) | 16 | 36.8 | ||
3 | 6 (16) | 2 | 65.8 (59–69) | 4:2:0:0 | 75 (50–100) | 6 | 23.5 | ||
4 | 0 | – | – | – | – | – | – | – | |
5 | 3 (8) | 3 | 66.3 (62–78) | 2:1:0:0 | – | 100 (50–200) | 3 | 11.6 |